The impact of administration of tranexamic acid in reducing the use of red blood cells and other blood products in cardiac surgery

Table 4 Univariate analysis of the effects of tranexamic acid administration on outcomes of interest.

Outcome measure	TA group (n = 3359)	NTA group (n = 832)	Odds ratio (95% CI)	p value
RBC transfusion (n, %)	1513 (45)	420 (51)	0.80 (0.69, 0.94)	0.005
FFP Transfusion (n, %)	288 (8.6)	95 (11)	0.78 (0.57, 0.93)	0.011
Any blood product transfusion (n, %)	1543 (46)	427 (51)	0.81 (0.69, 0.94)	0.005
Return to Theatre (n, %)	160 (4.8)	69 (8.3)	0.55 (0.41, 0.74)	<0.001
ICU stay > 1 day (n, %)	735 (22)	198 (24)	0.90 (0.75, 1.07)	0.234

Univariate analysis of the effects of tranexamic acid administration on outcomes of interest. The univariate analysis showed that the odds of receiving a transfusion or returning to theatre for bleeding were less in patients in tranexamic acid group, but that there was no difference in the proportion of patients staying for more than 1 day
(TA – tranexamic acid, NTA – no tranexamic acid, RBC – red blood cells, FFP – fresh frozen plasma, ICU – intensive care unit, CI – Confidence interval, n – number) (p < 0.05, statistically significant)

ISSN: 1471-2253